nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Comparative efficacy and safety of treatments for secondary Raynaud's phenomenon: a systematic review and network meta-analysis of randomised trials
|
Khouri, Charles |
|
|
1 |
4 |
p. e237-e246 |
artikel |
2 |
Complications and adverse events of unicompartmental versus total knee replacement
|
Sayers, Adrian |
|
|
1 |
4 |
p. e199-e200 |
artikel |
3 |
Correction to Lancet Rheumatol 2019; 1: e229–36
|
|
|
|
1 |
4 |
p. e205 |
artikel |
4 |
Correction to Lancet Rheumatol 2019; 1: e76–77
|
|
|
|
1 |
4 |
p. e205 |
artikel |
5 |
Correction to Lancet Rheumatol 2019; 1: e23–34
|
|
|
|
1 |
4 |
p. e205 |
artikel |
6 |
Disease heterogeneity in antineutrophil cytoplasmic antibody-associated vasculitis: implications for therapeutic approaches
|
Ford, Julia A |
|
|
1 |
4 |
p. e247-e256 |
artikel |
7 |
For lupus trials, the answer might depend on the question
|
Merrill, Joan T |
|
|
1 |
4 |
p. e196-e197 |
artikel |
8 |
Low-dose IL-2 for patients with systemic lupus erythematosus
|
He, Jing |
|
|
1 |
4 |
p. e203 |
artikel |
9 |
Low-dose IL-2 for patients with systemic lupus erythematosus – Authors' reply
|
Humrich, Jens Y |
|
|
1 |
4 |
p. e203-e204 |
artikel |
10 |
Medical cannabis: bridging the evidence gap
|
The Lancet Rheumatology, |
|
|
1 |
4 |
p. e195 |
artikel |
11 |
Misconceptions of arthritis and age: shake me, I rattle
|
Harding, Emilia |
|
|
1 |
4 |
p. e207 |
artikel |
12 |
Opioid use, postoperative complications, and implant survival after unicompartmental versus total knee replacement: a population-based network study
|
Burn, Edward |
|
|
1 |
4 |
p. e229-e236 |
artikel |
13 |
Raynaud's phenomenon: no net effects of vasodilators in a network analysis
|
Jaeger, Veronika K |
|
|
1 |
4 |
p. e200-e202 |
artikel |
14 |
Repurposing antidiabetic medications for gout: the potential of sodium glucose co-transporter 2 inhibitors
|
Neogi, Tuhina |
|
|
1 |
4 |
p. e197-e199 |
artikel |
15 |
Research in Brief
|
Thorley, Jennifer |
|
|
1 |
4 |
p. e206 |
artikel |
16 |
The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program
|
Li, JingWei |
|
|
1 |
4 |
p. e220-e228 |
artikel |
17 |
The nosology of systemic sclerosis: how lessons from the past offer new challenges in reframing an idiopathic rheumatological disorder
|
Lescoat, Alain |
|
|
1 |
4 |
p. e257-e264 |
artikel |
18 |
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial
|
Furie, Richard A |
|
|
1 |
4 |
p. e208-e219 |
artikel |